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SUMMARY
Background—In a recent double-blinded clinical trial the probiotic combination of L-NCFM 
and B-LBi07 reduced bloating symptoms in patients with functional bowel disorder; an effect 
more evident in those who reported abdominal pain. In mice, L-NCFM but not B-LBi07 induced 
colonic MOR and CB2 expression and reduced visceral sensitivity.
Aims—To determine if L-NCFM was the active component in the clinical trial and to investigate 
the mechanism of action in humans with mild to moderate abdominal pain.
Methods—Caucasian women (n=20) 18-70 years with mild to moderate abdominal pain were 
enrolled in a double-blind, two-armed, single-center study. Patients were given either L-NCFM 
alone or in combination with B-LBi07 for 21 days at a total dose of 2.0E10 CFU BID. Colonic 
biopsies were collected during un-sedated, un-prepped flexible sigmoidoscopy before and at the 
end of probiotic consumption. mRNA and immunostaining were then performed on these biopsies. 
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Patients kept symptom diaries for the 7 days prior to starting probiotic therapy and for the last 7 
days of therapy.
Results—L-NCFM alone, but not with B-LBi07, induced colonic MOR mRNA and protein 
expression, as well as downstream signaling, as measured by enterocyte STAT3-phosphorylation. 
In contrast, CB2 expression was decreased. Both treatment groups trended towards improvement 
in symptoms but the study was insufficiently powered to draw meaningful conclusions.
Conclusions—L-NCFM modulates MOR expression and activity, while the combination of L-
NCFM and B-LBi07 does not. This study provides a possible mechanism of action by which 
probiotics modulates pain sensation in humans.
Clinical Trial Number—clinicaltrials.gov ID (NCT#): NCT01064661
Keywords
abdominal pain; probiotics; lactobacillus; opioid receptors
INTRODUCTION
The intestinal microbiota has an important role in sustaining gastrointestinal (GI) function in 
healthy individuals.1 This has provided opportunities for targeting the intestinal microbiota 
by dietary interventions and/or microbial modifications aiming to improve GI symptoms in 
diseases associated with disrupted intestinal microbiota, e.g., Inflammatory Bowel Diseases 
(IBD) 2-5 and Functional Bowel Disorders (FBD),6-8 including Irritable Bowel Syndrome 
(IBS).9 However, the preferred probiotic intervention for specific conditions and the 
mechanism/s by which probiotics exert/induce their beneficial effects is still unclear.
L-NCFM is a lactobacillus strain commercially available in the United States since the 
1970s that has been investigated for numerous beneficial effects,10 including decreased 
incidence of pediatric diarrhea10 and enhancement of regulatory T-cell function in the T-cell 
transfer model of murine colitis.11 Data from animal studies suggest that daily consumption 
of the probiotic bacteria L-NCFM at 2×1010 CFU/day can increase expression of mu opioid 
receptor (MOR) and cannabinoid receptor 2 (CB2) in the intestinal mucosa and that these 
mucosal effects are associated with decrease in intestinal pain sensation.12 In addition, in a 
randomized controlled clinical trial in patients with non-constipation functional bowel 
disorders we have recently found that a blend of the probiotic bacteria L-NCFM and B-
LBi07 BID (2×1011 CFU total probiotic bacteria per day) for 8 weeks significantly 
improved abdominal bloating and distention symptoms in the probiotics group (N=30) 
compared to the placebo group (N=27).13 Furthermore, secondary analyses of our data show 
that this effect was even more evident in the subgroup of patients who also reported 
abdominal pain. 13 This data suggest that the beneficial effect of these probiotic bacteria 
may be mediated through their effect on intestinal sensation mechanisms. Due to the limited 
available effective treatments for functional abdominal pain, as well as the recent findings 
regarding the beneficial effect of L-NCFM in both mice and in our human clinical trial, we 
conducted a pilot study in humans to investigate whether daily consumption of the probiotic 
bacteria L-NCFM alone or in combination with B-LBi07 is associated with increased 
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Caucasian women 18-70 years with active mild to moderate abdominal pain (having pain in 
at least 3 of the 10 days at a level between 3 and 7 on a 10 point Likert scale (0=no pain 
through 10=very severe pain) were investigated. Subjects were excluded if they had 
inflammation or structural abnormality of the digestive tract, a serious or unstable medical 
condition (e.g., uncontrolled blood pressure, thyroid function, insulin dependent diabetes 
mellitus), major psychiatric diagnosis, lactase deficiency, predisposition to infection, were 
pregnant or lactating, received antibiotic treatment or intentionally consumed probiotics 
during the 4 weeks prior to enrollment, or had taken analgesics or anti-inflammatory 
medications in the 10 days prior to recruitment. Patients were recruited from the Chapel Hill 
general population by advertisement. All subjects sign an informed consent and the study 
protocol was approved by the UNC Institutional Review Board.
Study Design
This was a double-blind, randomized two armed, single-center study. Study involved a two 
week run-in phase and a four week intervention phase and included three visits (Figure 1). 
At the screening visit, subjects completed study questionnaires to verify eligibility and 
collect sociodemographic information. Subjects filled out daily diaries during the last seven 
days of the run-in period. At the first trial visit biological specimens were collected and 
subjects were randomized into one of two arms to receive either the probiotic Lactobacillus 
acidophilus NCFM (L-NCFM) alone BID (2×1010 CFU total bacteria per day) or a dual 
probiotic blend, L-NCFM and Bifidobacterium lactis Bi-07 (B-LBi07) BID (2×1010 CFU 
total bacteria per day) (Danisco Inc. Madison, Wisconsin, USA). Randomization was carried 
by the UNC Investigational Drug Service (IDS) by random numbers. Subjects and 
investigators were blinded throughout the study. Subjects had a daily diary to fill out from 
days 21-30 of the intervention and returned for a second trial visit at the end of the 
intervention period, for repeated questionnaires and biological specimen collection.
Data and Sample Collection
Colonic mucosal samples were collected at baseline (study visit 1) and at the end of 
intervention (study visit 2). Mucosal biopsies were obtained with cold biopsy forceps from 
the recto-sigmoid colon 15 to 20cm above the anal verge. To avoid any possible effect of 
intestinal preparation on the intestinal immune function, all samples were collected during 
an un-prepped flexible sigmoidoscopy. Biopsies were collected for routine histology and for 
mRNA analysis of the opioid receptor genes MOR and CB2. Biopsies were either frozen 
immediately at -80°C or placed in 1 mL of RNAlater™ for 24 hours and then frozen at 
-80°C for subsequent immunohistochemistry and RT-PCR analysis, respectively.
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Real-time polymerase chain reaction (RT-PCR)
Total RNA was isolated from mucosal biopsies using the Rneasy kit (Qiagen, Valencia, 
CA), according to the manufacturer’s instructions and treated with RNase-free DNase I 
(Roche Diagnostics Corporation, Indianapolis, IN). 500 ng of RNA was subjected to a 
reverse transcription reaction to form cDNA, and real-time PCR was then performed as 
previously described.14 Relative fold-changes were determined using the ΔCT or ΔΔCT 
calculation method as previously described.14 The primer sequences used were as follows: 
ACTB15 : F:5’-TCACCCACACTGTGCCCATCTACG -3’ and 5’-
CAGCGGAACCGCTCATTGCCAATG -3’; OPRM115 : F: 5’-
ATGCCAGTGCTCATCATTAC -3’ and R: 5’-GATCCTTCGAAGATTCCTGTCCT -3’; 
CB2: F: 5’-GCTAAGTGCCCTGGAGAACGT -3’ and R: 5’- TCAGCCCCAGCCAAGCT 
-3’.
Histology and Immunostaining
Intestinal biopsies from un-prepped flexible sigmoidoscopy samples from each patient pre- 
and post-treatment with probiotics were flushed with ice-cold PBS, fixed in 10% formalin 
for 24 hrs, and then embedded in paraffin. IHC staining for pSTAT3 (Y705) (Cell Signaling 
Technology Inc.; Beverly, MA, reactive to mouse, human, monkey, and rat) was performed 
according to the manufacturer’s specifications, at a 1:50 dilution as previously described16. 
Immunostaining for MOR and CB2 were performed as follows: sections were deparaffinized 
using Safeclear® (Fisher Protocol, Fair Lawn, NJ) for 20 minutes and rehydrated under 
serial ethanol concentrations. After permeabilization during 5 min in PBS containing 0.1 % 
triton X-100 at 4°C, sections were incubated for 15 min with 1.5 % goat normal serum and 
15 min with blocking buffer (1% BSA in milk) to minimize non-specific adsorption of the 
antibodies. The tissues were subsequently incubated with the rabbit polyclonal primary 
antibody directed against human MOR (1:100, Tebu-bio, Le-Perray-en-Yvelines, France) or 
human CB2 (1:10, Alpha Diagnostic, San Antonio, CA) overnight at 4°C . Sections were 
then rinsed in 0.1M PBS containing 0.05% triton X-100 and incubated in secondary 
antibody for 1 h at room temperature with Alexa 488 goat anti-rabbit IgG conjugated to 
FITC fluorochrome (dilution 1:100; Dako Laboratories, Carpinteria, CA). Then slides were 
counterstained with Hoescht solution (0.125 mg/mL) and mounted with ProLong Gold 
antifade reagent (Invitrogen).Negative controls consisted of staining with normal rabbit 
serum instead of specific antibody. Immunofluorescence was visualized under a 
fluorescence microscope (Leica, Bensheim, Germany). Positive-staining epithelial cells 
were quantified by eye in all captured images in a blinded fashion.
Statistical Analysis
Two-group analysis of RT-PCR data was performed using non-parametric t-tests (Mann-
Whitney). IF analysis was performed using standard two-tailed t-tests. Comparison of 
clinical outcomes was performed using standard, two-tailed t-tests. Correlation analysis was 
by Spearman’s non-parametric correlation.
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A total of 20 Caucasian women mean age 36.6 were investigated. Ten subjects (mean age 
28.9 years; mean bloating severity score 5.80; mean pain 4.0; and mean IBS-SSS score 304) 
received the combined intervention with L-NCFM and B-LBi07 and 10 subjects (mean age 
43.6 years; mean bloating severity score 5.70; mean pain 3.0; and mean IBS-SSS score 283) 
received only L-NCFM.
Real-time PCR analysis of pre- to post-probiotic intervention with L-NCFM and B-LBi07 or 
L-NCFM alone was associated with an increase in ΔCt of 3.79, demonstrating mu-opioid 
receptor (MOR)induction (13.8-fold, Figure 2A); in contrast, pre- to post-intervention 
Cannabinoid 2 (CB2) expression was found to be slightly (~2-fold) decreased (Figure 2B). 
Additionally, analysis of MOR expression on a per-patient-basis showed that patients treated 
with L-NCFM alone had a 39.9-fold pre- to post-intervention increase in the mRNA levels 
of the receptor while patients treated with both probiotics did not have a statistically 
significant increase in MOR expression (Figure 2C). Similarly, the decrease in CB2 mRNA 
was driven primarily by a ~4-fold decrease in expression in the NCFM group, while the 
dual-probiotic group showed no significant change in expression (Figure 2D). To further 
validate our RT-PCR findings we looked at MOR expression using immunofluorescence 
staining in the colonic mucosal samples of patients before and after receiving L-NCFM. 
Quantification of the number of positive-staining enterocytes found a significant change in 
mucosa-associated MOR staining (~2-fold, from 19.8 to 39.4, P = 0.0231, n = 4/group) after 
treatment with L-NCFM but not with dual probiotic therapy (P =0.4824) (Figure 3A&B).
Together, these data demonstrate that in patients with mild to moderate abdominal pain, 
treatment with the probiotic L-NCFM results in increased expression of colonic MOR. 
However, this finding alone does not demonstrate if there is a change in downstream 
signaling events resulting from the increased expression of the receptor. To address this, we 
measured phosphorylation of mucosal STAT3 (known to be downstream of enterocyte-
MOR activation)14, using samples from patients before and after treatment with L-NCFM. 
We found that post-treatment, patients given L-NCFM had increased levels of colonic and 
stromal pSTAT3 staining compared to before treatment (Figure 4).
Although this study was designed to look at the effect(s) of the probiotic interventions on the 
mucosal opioid receptor gene and was not powered to investigate potential clinical effects, 
we still performed analysis to see if there were any pre- to post-intervention changes in the 
clinical outcomes we measured and if changes in any of these clinical outcomes correlated 
with changes in MOR expression. Both intervention groups tended to have improvement in 
several clinical measures following probiotic interventions including in FBD symptoms 
severity scores (IBS-SSS)17, bloating severity, number of daily bowel movements (BMs), 
daily wellbeing, and number of days with abdominal pain (Table 1). Interestingly, the L-
NCFM-alone group did have a statistically significant decrease in the number of daily BMs, 
while this was not observed in the dual-probiotic group. There were no significant 
differences in clinical outcomes between the two treatment groups (Table 2). Analysis on 
the entire study population (including patients from both interventional arms) did not reveal 
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significant correlations between MOR mRNA levels and/or changes in probiotic-mediated 
MOR induction after therapy and clinical outcomes measures (data not shown).
DISCUSSION
Our study has several strengths: the design included a seven day run-in period that enabled 
careful selection of study subjects, we focused on abdominal pain as the primary clinical 
outcome, and the pre- and post- intervention mucosal samples were collected from un-
prepped colons.
Looking at the physiological data, we found that administration of L-NCFM but not the 
combination of L-NCFM and B-LBi07 induced increased levels of MOR mRNA expression. 
We were also able to establish that induction of MOR mRNA was correlated with enhanced 
protein expression by IHC, as well as STAT3 downstream enterocyte signaling, which is not 
always the case.18, 19 Interestingly, our study found that administration of L-NCFM alone 
was associated with decreased CB2 expression, unlike what was seen in mice, while there 
was no significant change in CB2 expression in patients given both probiotics. The lack of 
effect on MOR mRNA expression and STAT3 signaling in the group receiving the probiotic 
combination can be explained by the lower dose of L-NCFM in this group or by a possible 
competitively inhibiting effect of B-LBi07 on colonization or the physiologic effect of the 
bio-active L-NCFM strain.12
Previous clinical work established that administration of L-NCFM and B-LBi07 improved 
bloating symptoms, particularly in patients with abdominal pain13.The goal of our study was 
to investigate the physiological effects of L-NCFM and B-LBi07 and it was not powered to 
investigate potential clinical effects. However, we did find that both intervention groups 
tended to improve in several clinical measures following probiotic interventions. The 
statistically significant decrease in the number of daily bowel movements in the L-NCFM 
group is consistent with our physiological findings since the L-NCFM-alone group was the 
only treatment group to show an induction of MOR, which is known to suppress gut 
motility20.Together with the effects of L-NCFM on MOR expression our physiological 
findings suggest that L-NCFM is the primary inducer of physiological changes as related to 
mucosal opioid receptor expression and signaling.
Interestingly, while the clinical outcome data suggests similar outcomes for single and dual-
probiotic therapy, the physiological data showed significant differences between the two 
groups. This could suggest that MOR induction is not the only explanation for the beneficial 
effects of the probiotic intervention. Indeed, recent studies have shown that certain 
probiotics can affect brain activity in regions related to central processing of visceral 
sensation21 and that certain drugs can prevent opioid-induced bowel dysfunction without 
interfering with analgesia.22 It is also possible that any enhancement of clinical outcomes by 
the L-NCFM-alone group compared to the dual probiotic group were masked by the low 
power of the study. Nevertheless, our study findings provides a solid basis for pursuing 
further clinical trials to investigate the clinical relevance of the L-NCFM-induced increase in 
MOR expression and the clinical efficacy of L-NCFM in treating abdominal pain. Future 
studies should consider longer period of intervention and including another arm with B-
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LBi07 alone to help clarify the significance of enhancing the mu-opioid receptor and 
diminishing the cannabinoid receptors.
Another implication of this work is the potential beneficial effect of L-NCFM in patients 
with IBD. Studies in zebrafish23 and mice14, 24 have demonstrated that activation of MOR 
signaling is protective against intestinal injury and helps restore the epithelial barrier. This 
property of MOR signaling has recently been shown to be of clinical benefit in a case 
report25 of a patient with immunosuppressive IBD. Furthermore, a recent murine study has 
shown that L-NCFM is protective against T-cell transfer colitis in mice,11 a model known to 
be ameliorated by activation of MOR signaling.26 Thus, L-NCFM-mediated induction of 
MOR could be an excellent modality to induce targeted, colonic epithelial MOR in human 
patients for the treatment of IBD, warranting further clinical studies outside of the scope of 
the work presented here focusing on abdominal pain.
In conclusion, we replicated in humans the animal model observation of increased MOR 
mRNA expression and demonstrated that this increase in MOR mRNA expression is 
associated with increased mucosal protein expression and post-receptor STAT3 activation. 
Our data provides the first evidence for a probiotic effect on opioid-mediated pathways in 
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Figure 1. Study design
A randomized, double blind pilot study with a 7 days run-in phase and a 30 day single or 
dual probiotic intervention phase. Patients completed a 7-day symptom diary during the run-
in period and during the last 7 days of the intervention period. Mucosal biopsies were taken 
from unprepped colon pre and post probiotic interventions.
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Figure 2. Probiotic therapy in human patients induces increased levels of hMOR mRNA in 
human colonic mucosa, driven by L-NCFM
A&B) Comparison by real-time PCR of expression levels pre- and post- treatment with one 
or both probiotics. For analysis, results from both the single- and dual-probiotic arms were 
pooled, and were performed without tracking per-patient changes. A) Real-time PCR shows 
an increase in the ΔCt and thus expression of hMOR mRNA in patients with abdominal pain 
receiving either one or both probiotics; -21.44 vs -17.65, P=0.0349, N=14/group. B) Real-
time PCR shows a decrease in the ΔCt and thus expression of hCB2 mRNA in patients 
receiving either one or both probiotics; 1.287 vs. -2.396, P=0.0190, N=13/group.C) Per-
patient increase in hMOR mRNA expression after treatment with one or both probiotics 
showed a 39.9-fold induction in patients given L-NCFM alone (P =0.0313). No significant 
induction was seen in patients given both L-NCFM and B-LBi07. D) Per-patient decrease in 
CB2 mRNA expression after treatment with L-NCFM alone showed a 4.15-fold decreased 
in the L-NCFM group (P=0.032). No change in expression was seen in patients given both 
probiotics.
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Figure 3. Increase in levels of protein expression in human colonic mucosa by L-NCFM
A) Immunofluorescence of colonic mucosa samples of patients given L-NCFM alone 
showing increased MOR expression of colonic-mucosa. Representative of 4 independent 
experiments. White arrow heads point to colonic-mucosa-associated MOR. Scale bars equal 
50 μm. B) Bar graph shows change in positive staining enterocytes after treatment with one 
or both probiotics; only the L-NCFM showed a statistically significant induction; 2.17-fold, 
P=0.0231, n=4/group.
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Figure 4. Increase in post-receptor downstream signaling in human colonic mucosa by L-NCFM
Immunostaining is for pSTAT3 (Y705), with staining indicated by white arrow heads. 
Representative of 4 patients. Scale bars are 100 μm. Mean pre- to post-intervention increase 
in staining was 18 more cells after treatment (19.8 to 39.4 post-treatment, P=0.0469, n=4).
Ringel-Kulka et al. Page 13

























Ringel-Kulka et al. Page 14
Table 1
Clinical outcome measures after probiotic administration
Analysis by paired t-tests.
Outcome
NCFM+B-LBi07 (N = 10) NCFM (N = 7)
Pre Post Pre Post
IBS-SSS 304 182** 283 173
Bloating severity 5.80 3.30* 6.29 2.57 (P=0.1)
Number of daily BMs 1.29 1.40 1.61 1.44*
Daily wellbeing 3.28 3.61 3.04 3.38
Number of days with abdominal pain 7.00 3.80* 4.57 3.86
*
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Table 2
Clinical outcome measure comparisons between treatment groups
Values are reported as mean±SEM. Analysis is by two-tailed t-test
Outcomes (Post-Pre) NCFM+B-LBi07 NCFM P-value
IBS-SSS -122±33 -100±36 0.81
Bloating severity -2.5±0.9 -3.7±0.8 0.36
Number of daily BMs 0.11±0.15 -1.7±0.07 0.35
Daily wellbeing 0.33±0.16 0.34±0.17 0.99
Number of days with abdominal pain -3.2±1.1 -0.71±0.27 0.15
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